menu
    • menu
    [{"orgOrder":0,"company":"CellCentric","sponsor":"Morningside Venture Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"CCS1477","moa":"Acetyltransferases p300\/CBP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Morningside Venture Investments","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Morningside Venture Investments"},{"orgOrder":0,"company":"CellCentric","sponsor":"BrightEdge","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Inobrodib","moa":"p300\/CBP bromodomain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CellCentric \/ BrightEdge","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ BrightEdge"},{"orgOrder":0,"company":"CellCentric","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Inobrodib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Not Applicable"},{"orgOrder":0,"company":"CellCentric","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Inobrodib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Pfizer Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by CellCentric

    Menu

    CellCentric

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CellCentric

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            CellCentric

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inobrodib,Pomalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            CellCentric Announces $25m Strategic Investment from Pfizer

                            Details : The company intends to use the net proceeds to fund the development of CCS1477 (inobrodib), its p300/CBP inhibitor to treat specific types of cancer including haematological malignancies and multiple myeloma.

                            Brand Name : CCS1477

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 11, 2023

                            Lead Product(s) : Inobrodib,Pomalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CellCentric

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            CellCentric

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inobrodib,Pomalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CellCentric To Present Inobrodib Phase I Multiple Myeloma Efficacy And Safety Data At The American Society Of ...

                            Details : Inobrodib (CCS1477) is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers, to treat late stage multiple myeloma patients.

                            Brand Name : CCS1477

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 04, 2022

                            Lead Product(s) : Inobrodib,Pomalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CellCentric

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            CellCentric

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inobrodib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BrightEdge

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CellCentric Secures Investment from The American Cancer Society’s Impact Venture Capital Fund

                            Details : The funding will be used to further progress the clinical development of its ground-breaking, targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional significant investment from existing lead investor, Morningside Inve...

                            Brand Name : CCS1477

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 26, 2022

                            Lead Product(s) : Inobrodib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BrightEdge

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CellCentric

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            CellCentric

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inobrodib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Morningside Venture Investments

                            Deal Size : $33.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            CellCentric Raises $33m to Broaden Clinical Trials of its First-in-Class p300/CBP Inhibitor, CCS1477

                            Details : CCS1477 is a novel drug in Phase I/II clinical trials to treat late stage prostate cancer, haematological malignancies as well as tumours with p300/CBP mutations. CellCentric plans to investigate CCS1477 both as a monotherapy and in combination with stan...

                            Brand Name : CCS1477

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 22, 2020

                            Lead Product(s) : Inobrodib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Morningside Venture Investments

                            Deal Size : $33.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth